Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Sanofi Pasteur SA
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 5 ans
Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an Inactivated Influenza Vaccine Administered via the Intramuscular Route
- To describe the cellular immune response per age group (adults or elderly) and vaccine group (ID influenza or IM comparator vaccines) before vaccination, and, 7 days, 10 days, 14 days, 21 days, 180 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 5 ans
Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in 50 to 59 Years old Adults
• To demonstrate that the ID investigational vaccine is at least as immunogenic as the IM reference vaccine in terms of geometric mean titer (GMT) after vaccination. • If non-inferiority is demonstr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 5 ans
Lot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults
To demonstrate that the three different industrial lots of the intradermal (ID) investigational vaccine induce an equivalent immune response.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 5 ans
Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children
To describe the safety of the 9µg formulation of the inactivated, split-virion influenza vaccine administered by the intradermal (ID) route in children aged 6 to 35 months and 3 to 8 years.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 5 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months
• To describe the immune response of each candidate vaccine 21 days after each vaccination by hemagglutination inhibition (HAI) and seroneutralization (SN) testing in all subjects. • To describe the a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3